恩帕格利弗洛辛在心脏衰竭中的心脏和功能:来自EMPEROR的见解
在PubMed上查看摘要
概括
此摘要是机器生成的。恩帕格利弗洛辛有助于慢性心力衰竭患者减少排泄率,减少心血管事件和住院. 它还显著减缓了功能衰退,包括病的各个阶段.
科学领域
- 心脏病学
- 肝脏病学
- 药理学
背景情况
- 在EMPEROR- Reduced试验中,研究了empagliflozin对心力衰竭的作用.
- 之前的研究结果显示,在患有或没有糖尿病的HFrEF患者中,empagliflozin减少了心血管死亡/ HF住院,并减缓了功能下降.
研究的目的
- 分析Empagliflozin对HFrEF患者心血管和结局的影响.
- 评估empagliflozin对患有和没有慢性病 (CKD) 的患者的影响.
主要方法
- 一个预先规定的EMPEROR-Reduced试验分析.
- 根据基线CKD状态 (eGFR < 60ml/ min/ 1. 73m2或ACR > 300mg/ g) 分类患者.
- 主要结局包括心血管死亡/HF住院,HF住院总数和eGFR倾斜值;脏综合结局也被评估.
主要成果
- 在患有或没有慢性病的患者中,恩帕格利弗洛辛降低了主要结局 (心血管疾病死亡/ 肝炎住院) 和肝炎住院总数.
- 在CKD和非CKD组中,Empagliflozin减缓了eGFR的下降.
- 在患有CKD和没有CKD的患者中,结合性结局风险同样降低.
- 在各种基线功能水平中,益处一致,包括低至20毫升/ 分钟/ 1. 73平方米的EGFR.
结论
- 在HFrEF患者中,无论慢性病状况如何,Empagliflozin对关键疗效结果有显著的益处.
- 这种药物有效地减缓了患有CKD和没有CKD的患者的功能衰退.
- 恩帕格利弗洛辛在患有慢性病的患者中耐受良好.
相关概念视频
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...

